Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study
- 1 October 2016
- journal article
- research article
- Published by Elsevier BV in Epilepsy Research
- Vol. 126, 201-210
- https://doi.org/10.1016/j.eplepsyres.2016.08.001
Abstract
No abstract availableFunding Information
- Eisai Ltd.
This publication has 36 references indexed in Scilit:
- Management of Seizures following a StrokeDrugs & Aging, 2012
- Combining antiepileptic drugs—Rational polytherapy?Seizure, 2011
- Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsyEpilepsia, 2011
- Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemmaEpilepsia, 2011
- Changes in seizure severity and quality of life in patients with refractory partial epilepsyEpilepsy & Behavior, 2010
- Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009Epilepsia, 2010
- Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: An indirect comparison of treatment-emergent adverse events using meta-analytic techniquesEpilepsy & Behavior, 2009
- New Developments in Antiepileptic Drug Resistance: An Integrative ViewEpilepsy Currents, 2009
- Effectiveness of lamotrigine in clinical practice: Results of a retrospective population-based studyEpilepsy Research, 2005
- Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic SeizuresEpilepsia, 1981